Patents by Inventor Haijun Tong

Haijun Tong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Subject-Specific Tumor Inhibiting Cells and the Use Thereof
    Publication number: 20240269177
    Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.
    Type: Application
    Filed: August 17, 2023
    Publication date: August 15, 2024
    Inventors: HUA GU, Gang G. Xu, Adeline Gadzinski, Haijun Tong
  • Subject-specific tumor inhibiting cells and the use thereof
    Patent number: 11766455
    Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: September 26, 2023
    Assignees: EZY Biotech LLC, Adaerata, Limited Patnership
    Inventors: Hua Gu, Gang G Xu, Adeline Gadzinski, Haijun Tong
  • COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF
    Publication number: 20220402917
    Abstract: A biaryl compound. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 30, 2020
    Publication date: December 22, 2022
    Inventors: Lingyun WU, Cailin WANG, Xiongbin XU, Haijun TONG, Shuhui CHEN
  • COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20220175917
    Abstract: The present invention relates to a combination of a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof which are used as an IAP inhibitor, and an immune checkpoint inhibitor; and use of the combination in the preparation of a cancer treatment drug.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 9, 2022
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yingchun LIU, Zhaobing XU, Shuhua HAN, Lihong HU, Charles Z. DING, Yuanfeng XIA, Haijun TONG, Lihua HE, Xin TIAN
  • Subject-Specific Tumor Inhibiting Cells and the Use Thereof
    Publication number: 20200390810
    Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.
    Type: Application
    Filed: December 14, 2018
    Publication date: December 17, 2020
    Inventors: HUA GU, Gang G Xu, Adeline Gadzinski, Haijun Tong